Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain

Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain

The proto-oncogene <i>MDM2</i> is frequently amplified in many human cancers and its overexpression is clinically associated with a poor prognosis. The oncogenic activity of MDM2 is demonstrated by its negative regulation of tumor suppressor p53 and the substrate proteins involved in DNA...

Full description

Bibliographic Details
Main Authors:	Viktoria K. Ilic, Olga Egorova, Ernest Tsang, Milena Gatto, Yi Wen, Yong Zhao, Yi Sheng
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Biomolecules
Subjects:	MDM2 E3 ligase inhibitor p53 MDMX ubiquitination
Online Access:	https://www.mdpi.com/2218-273X/12/5/643

Similar Items

A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize
by: Pavlína Kosztyu, et al.
Published: (2019-04-01)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01)

Controlling the Mdm2-Mdmx-p53 Circuit
by: David L. Waning, et al.
Published: (2010-05-01)

Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells
by: Chong Gao, et al.
Published: (2019-01-01)

MDMX is essential for the regulation of p53 protein levels in the absence of a functional MDM2 C-terminal tail
by: Jack D. Sanford, et al.
Published: (2021-09-01)

Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach
by: Keting Li, et al.
Published: (2024-12-01)

Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
by: Yujun Zhao, et al.
Published: (2013-07-01)

MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters
by: Kester Mo Henningsen, et al.
Published: (2021-12-01)

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
by: Jiang-Jiang Qin, et al.
Published: (2017-12-01)

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
by: Xiang Li, et al.
Published: (2021-09-01)

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
by: Yali Wang, et al.
Published: (2022-06-01)

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
by: Si-Min Qi, et al.
Published: (2020-04-01)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
by: Vera V. Grinkevich, et al.
Published: (2022-06-01)

Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method
by: Mengxin Li, et al.
Published: (2019-01-01)

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
by: Javier Octavio Mejía-Hernández, et al.
Published: (2022-08-01)

Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53
by: Chan, Jane Vin, et al.
Published: (2018)

Molecular and Biochemical Techniques for Deciphering p53-MDM2 Regulatory Mechanisms
by: Konstantinos Karakostis, et al.
Published: (2020-12-01)

Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells
by: Rati Lama, et al.
Published: (2022-11-01)

MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells
by: Renier C. Heijkants, et al.
Published: (2022-09-01)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
by: Venkatesh, Byrappa, et al.
Published: (2016)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
by: Yuta Mitobe, et al.
Published: (2023-08-01)

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
by: Lin W, et al.
Published: (2024-01-01)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
by: Johanna Huun, et al.
Published: (2017-04-01)

Oncogenic functions of hMDMX in <it>in vitro </it>transformation of primary human fibroblasts and embryonic retinoblasts
by: van der Burg Marja JM, et al.
Published: (2011-09-01)

TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2
by: Xiaoxi Lv, et al.
Published: (2023-04-01)

Evolution of the p53-MDM2 pathway
by: Emma Åberg, et al.
Published: (2017-08-01)

Methoxyphenyl Imidazolines as Potential Activators of p53
by: Daniil R. Bazanov, et al.
Published: (2022-11-01)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
by: Yuta Mitobe, et al.
Published: (2023-07-01)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
by: Haohao Zhu, et al.
Published: (2022-07-01)

Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets
by: Emil Bulatov, et al.
Published: (2018-05-01)

p53 and MDM2 protein expression in actinic cheilitis
by: Maria da Conceição Andrade de Freitas, et al.
Published: (2008-12-01)

Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status
by: Rati Lama, et al.
Published: (2022-08-01)

Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch
by: Julija Mozūraitienė, et al.
Published: (2015-01-01)

The Dual Roles of MAGE-C2 in p53 Ubiquitination and Cell Proliferation Through E3 Ligases MDM2 and TRIM28
by: Yunshan Liu, et al.
Published: (2022-07-01)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
by: Helei Hou, et al.
Published: (2019-08-01)

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
by: Xin Han, et al.
Published: (2022-05-01)

MDM2-C Functions as an E3 Ubiquitin Ligase
by: Kim JY, et al.
Published: (2020-08-01)

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
by: Ali M. Alaseem
Published: (2023-10-01)

Association of MDM2 Overexpression in Ameloblastomas with <i>MDM2</i> Amplification and BRAF<sup>V600E</sup> Expression
by: Konstantinos I. Tosios, et al.
Published: (2024-02-01)

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
by: Mengyang Chang, et al.
Published: (2022-08-01)